Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
Total Valuation
Compass Therapeutics has a market cap or net worth of $927.45M. The enterprise value is $691.36M.
Market Cap$927.45M
Enterprise Value$691.36M
Share Statistics
Compass Therapeutics has 180,087,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding180,087,920
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Compass Therapeutics’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -35.25%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-35.25%
Return on Capital Employed (ROCE)-0.35
Revenue Per Employee0.00
Profits Per Employee-1.90M
Employee Count35
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Compass Therapeutics is ―. Compass Therapeutics’s PEG ratio is -0.76.
PE Ratio―
PS Ratio0.00
PB Ratio4.30
Price to Fair Value4.30
Price to FCF-17.22
Price to Operating Cash Flow-19.37
PEG Ratio-0.76
Income Statement
In the last 12 months, Compass Therapeutics had revenue of 0.00 and earned -66.49M in profits. Earnings per share was -0.42.
Revenue0.00
Gross Profit0.00
Operating Income-72.84M
Pretax Income-66.49M
Net Income-66.49M
EBITDA-72.84M
Earnings Per Share (EPS)-0.42
Cash Flow
In the last 12 months, operating cash flow was -49.14M and capital expenditures -11.00K, giving a free cash flow of -49.17M billion.
Operating Cash Flow-49.14M
Free Cash Flow-49.17M
Free Cash Flow per Share-0.27
Dividends & Yields
Compass Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.21
52-Week Price Change117.30%
50-Day Moving Average5.90
200-Day Moving Average4.29
Relative Strength Index (RSI)36.82
Average Volume (3m)1.99M
Important Dates
Compass Therapeutics upcoming earnings date is May 13, 2026, Before Open (Confirmed).
Last Earnings DateMar 5, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Compass Therapeutics as a current ratio of 15.02, with Debt / Equity ratio of 4.99%
Current Ratio15.02
Quick Ratio15.02
Debt to Market Cap0.01
Net Debt to EBITDA0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Compass Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Compass Therapeutics EV to EBITDA ratio is -11.34, with an EV/FCF ratio of -16.80.
EV to Sales0.00
EV to EBITDA-11.34
EV to Free Cash Flow-16.80
EV to Operating Cash Flow-16.81
Balance Sheet
Compass Therapeutics has $208.91M in cash and marketable securities with $9.83M in debt, giving a net cash position of $199.08M billion.
Cash & Marketable Securities$208.91M
Total Debt$9.83M
Net Cash$199.08M
Net Cash Per Share$1.11
Tangible Book Value Per Share$1.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Compass Therapeutics is $12.72, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$12.72
Price Target Upside146.99% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-100.00%
EPS Growth Forecast-28.79%